Talecris Biotherapeutics claims that Prolastin-C is more concentrated and purified formulation of Prolastin, the only approved alpha1-augmentation therapy in Canada.
Prolastin-C and Prolastin are indicated for chronic augmentation and maintenance therapy in adults who have emphysema due to a genetic condition known as alpha1-antitrypsin (AAT) deficiency.
Talecris Portfolio Management & International Business senior vice president & general manager Joel Abelson said that Talecris research and development scientists continually strive to enhance the overall quality of the products by incorporating the latest advances in technology.